Optimizing the Regulatory Strategy for an Anti-cancer Drug
Certara scientists performed helped a small biotech company create a clinical pharmacology package for their NDA submission for a novel oncology drug.
Certara scientists performed helped a small biotech company create a clinical pharmacology package for their NDA submission for a novel oncology drug.
A M&S model was built to offer an alternate approach to dedicated timing studies to determine the best time to vaccinate pregnant women.
PRINCETON, NJ – Feb. 25, 2020 – Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease.
Introducing our three-part blog series on getting started with in-house development. In this series, we’re detailing some key aspects of how you can create and deploy your own mobile apps, for the purposes of stakeholder engagement and value communication, in-house—without the help of external agencies. Developing mobile apps in-house is increasingly popular compared to outsourced … Continued
This webinar will explain how pricing has evolved for the rare disease drug market and best practices for supporting value-based pricing.
Introducing our three-part blog series on getting started with in-house development. In this series, we’re detailing some key aspects of how you can create and deploy your own mobile apps, for the purposes of stakeholder engagement and value communication, in-house—without the help of external agencies. Developing mobile apps in-house is increasingly popular compared to outsourced … Continued
This blog discusses the development of pharmacokinetic CDISC data standards and the impact of building them for electronic regulatory submissions.
PRINCETON, NJ – Feb. 10, 2020 – Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
Introducing our three-part blog series on getting started with in-house development. In this series, we’re detailing some key aspects of how you can create and deploy your own mobile apps, for the purposes of stakeholder engagement and value communication, in-house—without the help of external agencies. Developing mobile apps in-house is increasingly popular compared to outsourced … Continued